Who
Pamela Wapnick
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Metagenomi Therapeutics.
In numbers
- Trades disclosed
- 21
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $50K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Apr 2024
- Last trade
- 8 Sep 2026
- Last filed
- 10 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 8 Sep 2026filed 10 Sep 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,2141,911 at $1.16 | filing |
| 8 Sep 2026filed 10 Sep 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,2171,911 at $1.16 | filing |
| 5 Jun 2026filed 10 Jun 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,7462,884 at $1.30 | filing |
| 5 Jun 2026filed 10 Jun 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,7492,884 at $1.30 | filing |
| 1 Apr 2026filed 3 Apr 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | MGX Metagenomi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —144,000 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | MGX Metagenomi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —144,000 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Code A | —24,000 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,5301,581 at $1.60 | filing |
| 5 Mar 2026filed 9 Mar 2026 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,5301,581 at $1.60 | filing |
| 5 Dec 2025filed 8 Dec 2025 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,7901,576 at $1.77 | filing |
| 1 Dec 2025filed 1 Dec 2025 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Code A | $192K120,000 at $1.60 | filing |
| 5 Sep 2025filed 1 Dec 2025 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,8531,576 at $1.81 | filing |
| 6 Jun 2025filed 9 Jun 2025 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,7581,576 at $1.75 | filing |
| 1 Apr 2025filed 3 Apr 2025 | MGX Metagenomi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —84,000 at $0.00 | filing |
| 1 Apr 2025filed 3 Apr 2025 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 5 Mar 2025filed 7 Mar 2025 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,3811,808 at $1.87 | filing |
| 5 Dec 2024filed 6 Dec 2024 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,9001,559 at $1.86 | filing |
| 5 Sep 2024filed 6 Sep 2024 | MGX Metagenomi TherapeuticsBiotechnology | SEC FORM 4 Sold | $18K6,265 at $2.88 | filing |
| 1 Apr 2024filed 3 Apr 2024 | MGX Metagenomi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —291,450 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.